---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-172060"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2022-06-10T23:59:59+00:00"
generated_at: "2026-06-25T02:47:35.295366+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CFO/COO and director Christopher Lowe resigns; June Bray appointed director; Monohon named PFO

## Summary
- Christopher Lowe resigned as board member (June 8) and as CFO/COO (effective June 10); separation includes $354,750 cash severance and equity acceleration.
- June Bray appointed as Class III director; receives initial option for 54,000 shares at $3.20, vesting over 3 years.
- Ted Monohon, current CAO and VP Finance, designated as principal financial officer; no change in compensation.
- Sublease with ICON Clinical Research for 601 Gateway Blvd, SF: term June 18, 2022 to Nov 30, 2023, optional extension; rent $16,692-$17,206/mo.
- Annual meeting: elected Lowe and Senner as directors, ratified BDO as auditor, approved say-on-pay.

## SEC filing metadata
- accession: 0001193125-22-172060
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2022-06-10T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/0001193125-22-172060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/d331287d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-172060
- JSON: https://secwatch.observer/filing/0001193125-22-172060.json
- Plain text: https://secwatch.observer/filing/0001193125-22-172060.txt

## Key facts
- Executive change
  Christopher Lowe resigned as Chief Financial Officer at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/0001193125-22-172060-index.htm
- Executive change
  Christopher Lowe resigned as Chief Operating Officer at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Operating Officer
  source text: Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/0001193125-22-172060-index.htm
- Executive change
  Christopher Lowe resigned as member of the Board of Directors at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: member of the Board of Directors
  source text: On June 8, 2022, Christopher Lowe, the Chief Financial Officer, Chief Operating Officer and a member of the Board of Directors (the “Board”) of the Company, resigned as a member of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/0001193125-22-172060-index.htm
- Executive change
  June Bray was appointed as Class III director at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: On June 9, 2022, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed June Bray to serve as a Class III director of the Company, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/0001193125-22-172060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.